Innovent Seeks Chinese Regulatory Approval for Proposed Biosimilar Bevacizumab - The Center for Biosimilars

Innovent Seeks Chinese Regulatory Approval for Proposed Biosimilar Bevacizumab  The Center for Biosimilars

Innovent Biologics, a China-based biopharmaceutical company, recently submitted a New Drug Application for its proposed bevacizumab biosimilar, IBI-305, ...